Have a feature idea you'd love to see implemented?
Let us know!
SKYE Skye Bioscience Inc
Price (delayed)
$4.17
Market cap
$126.51M
P/E Ratio
7.87
Dividend/share
N/A
EPS
$0.53
Enterprise value
$50.21M
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I
Highlights
The company's quick ratio has surged by 134% QoQ
SKYE's EPS has surged by 121% since the previous quarter and by 106% year-on-year
Key stats
What are the main financial stats of SKYE
Market
Valuations
Earnings
Shares outstanding
30.34M
Market cap
$126.51M
Enterprise value
$50.21M
Price to earnings (P/E)
7.87
Price to book (P/B)
1.67
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$20M
EBITDA
-$19.85M
Free cash flow
-$22.47M
Per share
Balance sheet
Liquidity
EPS
$0.53
Free cash flow per share
-$0.58
Book value per share
$2.5
Revenue per share
$0
TBVPS
$2.1
Total assets
$81.54M
Total liabilities
$5.73M
Debt
$190,994
Equity
$75.8M
Working capital
$74.18M
Debt to equity
0
Current ratio
14.19
Quick ratio
13.6
Net debt/EBITDA
3.84
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-30.8%
Return on equity
-37.7%
Return on invested capital
N/A
Return on capital employed
-26.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SKYE stock price
How has the Skye Bioscience stock price performed over time
Intraday
-2.57%
1 week
-24.32%
1 month
-11.46%
1 year
N/A
YTD
N/A
QTD
6.65%
Financial performance
How have Skye Bioscience's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.61M
Net income
-$21.24M
Gross margin
N/A
Net margin
N/A
Skye Bioscience's net income has surged by 51% YoY and by 50% QoQ
SKYE's operating income is up by 46% from the previous quarter and by 41% YoY
Growth
What is Skye Bioscience's growth rate over time
Valuation
What is Skye Bioscience stock price valuation
P/E
7.87
P/B
1.67
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
SKYE's EPS has surged by 121% since the previous quarter and by 106% year-on-year
The equity has grown by 4.1% from the previous quarter
Efficiency
How efficient is Skye Bioscience business performance
The ROA has soared by 94% YoY and by 62% from the previous quarter
The company's return on equity has surged by 66% QoQ
Dividends
What is SKYE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SKYE.
Financial health
How did Skye Bioscience financials performed over time
The current ratio has soared by 134% from the previous quarter
The company's quick ratio has surged by 134% QoQ
Skye Bioscience's debt is 100% lower than its equity
The debt to equity has plunged by 100% from the previous quarter and by 100% YoY
Skye Bioscience's debt has shrunk by 96% QoQ and by 96% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.